PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid Cancer

Cancer Immunology Research - Tập 3 Số 6 - Trang 620-630 - 2015
Jill J. Severson1, Hilary S. Serracino2, Valerica Mateescu2, Christopher D. Raeburn3,4, Robert C. McIntyre3,4, Sharon B. Sams2,4, Bryan R. Haugen1,2,4, Jena D. French1,4
11Department of Medicine, Division of Endocrinology, Metabolism, and Diabetes, University of Colorado, Anschutz Medical Campus, Aurora, Colorado.
22Department of Pathology, University of Colorado, Anschutz Medical Campus, Aurora, Colorado.
33Department of Surgery, University of Colorado, Anschutz Medical Campus, Aurora, Colorado.
44University of Colorado Cancer Center, University of Colorado, Anschutz Medical Campus, Aurora, Colorado.

Tóm tắt

Abstract Regional metastatic differentiated thyroid cancer (mDTC) provides a unique model in which to study the tumor–immune interface. These lymph node metastases persist for years, generally without progression to distant metastases. Although the immune system likely impedes disease progression, it is unsuccessful in eliminating disease. Our previous studies revealed that programmed death-1 (PD-1)+ T cells were enriched in tumor-involved lymph nodes (TILN). Tumor-associated leukocytes and tumor cells were collected from grossly involved lymph nodes from 12 patients to further characterize the phenotype and functional potential of mDTC-associated PD-1+ T cells. PD-1+CD4+ and PD-1+CD8+ T cells were enriched in 8 of 12 TILN samples. PD-1+ T cells coexpressed Tim-3 and CD69 and failed to downregulate CD27. CD8+ T cells, but not CD4+ T cells, from these samples were variably deficient in their ability to produce effector cytokines when compared with control TILNs that lacked resident PD-1+ T cells. PD-1+CD8+ T cells were capable of exocytosis but lacked intracellular perforin. Surprisingly, T-cell proliferative capacity was largely maintained in all samples. Thus, although PD-1 expression by mDTC-associated CD8+ T cells was associated with dysfunction, exhaustion was not complete. Notably, molecular markers of exhaustion did not translate to dysfunction in all samples or in CD4+ T cells. Regulatory T cells (Treg), PD-L1, and galectin-9 were commonly found in mDTC and likely contributed to the initiation of T-cell exhaustion and disease progression. Therapies that release the effects of PD-1 and Tim-3 and reduce the suppressive effects of Tregs may encourage tumor elimination in patients with mDTC. Cancer Immunol Res; 3(6); 620–30. ©2015 AACR.

Từ khóa


Tài liệu tham khảo

Howlader, 2011, Surveillance Epidemiology and End Results (SEER): Cancer Statistics Review 1975–2008

Mazzaferri, 1994, Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer, Am J Med, 97, 418, 10.1016/0002-9343(94)90321-2

Ito, 2006, Clinical significance of lymph node metastasis of thyroid papillary carcinoma located in one lobe, World J Surg, 30, 1821, 10.1007/s00268-006-0211-5

French, 2012, Programmed death-1+ T cells and regulatory T cells are enriched in tumor-involved lymph nodes and associated with aggressive features in papillary thyroid cancer, J Clin Endocrinol Metab, 97, E934, 10.1210/jc.2011-3428

Wherry, 2011, T cell exhaustion, Nat Immunol, 12, 492, 10.1038/ni.2035

Wherry, 2003, Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment, J Virol, 77, 4911, 10.1128/JVI.77.8.4911-4927.2003

Wherry, 2007, Molecular signature of CD8+ T cell exhaustion during chronic viral infection, Immunity, 27, 670, 10.1016/j.immuni.2007.09.006

Ahmadzadeh, 2009, Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired, Blood, 114, 1537, 10.1182/blood-2008-12-195792

Baitsch, 2011, Exhaustion of tumor-specific CD8(+) T cells in metastases from melanoma patients, J Clin Invest, 121, 2350, 10.1172/JCI46102

Fourcade, 2010, Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients, J Exp Med, 207, 2175, 10.1084/jem.20100637

Fourcade, 2012, CD8+ T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1, Cancer Res, 72, 887, 10.1158/0008-5472.CAN-11-2637

Matsuzaki, 2010, Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer, Proc Natl Acad Sci U S A, 107, 7875, 10.1073/pnas.1003345107

Riches, 2013, T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production, Blood, 121, 1612, 10.1182/blood-2012-09-457531

Wang, 2011, Early T cell signalling is reversibly altered in PD-1 T lymphocytes infiltrating human tumors, PLoS ONE, 6, e17621, 10.1371/journal.pone.0017621

Zhang, 2010, Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non–small cell lung cancer, Cell Mol Immunol, 7, 389, 10.1038/cmi.2010.28

Zippelius, 2004, Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance, Cancer Res, 64, 2865, 10.1158/0008-5472.CAN-03-3066

Yang, 2012, IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma, J Clin Invest, 122, 1271, 10.1172/JCI59806

Blackburn, 2009, Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection, Nat Immunol, 10, 29, 10.1038/ni.1679

Brooks, 2005, Intrinsic functional dysregulation of CD4 T cells occurs rapidly following persistent viral infection, J Virol, 79, 10514, 10.1128/JVI.79.16.10514-10527.2005

Crawford, 2014, Molecular and transcriptional basis of CD4(+) T cell dysfunction during chronic infection, Immunity, 40, 289, 10.1016/j.immuni.2014.01.005

Kassu, 2010, Regulation of virus-specific CD4+ T cell function by multiple costimulatory receptors during chronic HIV infection, J Immunol, 185, 3007, 10.4049/jimmunol.1000156

Kaufmann, 2007, Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction, Nat Immunol, 8, 1246, 10.1038/ni1515

Goding, 2013, Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma, J Immunol, 190, 4899, 10.4049/jimmunol.1300271

Phillips, 2007, Development of standard estrogen and progesterone receptor immunohistochemical assays for selection of patients for antihormonal therapy, Appl Immunohistochem Mol Morphol, 15, 325, 10.1097/01.pai.0000213135.16783.bc

Sallusto, 1999, Two subsets of memory T lymphocytes with distinct homing potentials and effector functions, Nature, 401, 708, 10.1038/44385

Betts, 2003, Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation, J Immunol Methods, 281, 65, 10.1016/S0022-1759(03)00265-5

Dong, 2002, Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion, Nat Med, 8, 793, 10.1038/nm730

Keir, 2006, Tissue expression of PD-L1 mediates peripheral T cell tolerance, J Exp Med, 203, 883, 10.1084/jem.20051776

Zhu, 2005, The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity, Nat Immunol, 6, 1245, 10.1038/ni1271

Gupta, 2012, Allograft rejection is restrained by short-lived TIM-3+PD-1+Foxp3+ Tregs, J Clin Invest, 122, 2395, 10.1172/JCI45138

Raimondi, 2006, Regulated compartmentalization of programmed cell death-1 discriminates CD4+CD25+ resting regulatory T cells from activated T cells, J Immunol, 176, 2808, 10.4049/jimmunol.176.5.2808

Jin, 2011, Mechanism of T cell exhaustion in a chronic environment, BMB Rep, 44, 217, 10.5483/BMBRep.2011.44.4.217

Badoual, 2013, PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer, Cancer Res, 73, 128, 10.1158/0008-5472.CAN-12-2606

Amarnath, 2011, The PDL1-PD1 axis converts human TH1 cells into regulatory T cells, Sci Transl Med, 3, 111ra120, 10.1126/scitranslmed.3003130

Kitazawa, 2007, Involvement of the programmed death-1/programmed death-1 ligand pathway in CD4+CD25+ regulatory T-cell activity to suppress alloimmune responses, Transplantation, 83, 774, 10.1097/01.tp.0000256293.90270.e8

Brahmer, 2010, Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates, J Clin Oncol, 28, 3167, 10.1200/JCO.2009.26.7609

Fransen, 2011, Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody, Clin Cancer Res, 17, 2270, 10.1158/1078-0432.CCR-10-2888

Hamid, 2013, Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma, N Engl J Med, 369, 134, 10.1056/NEJMoa1305133

Brose, 2014, Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial, Lancet, 384, 319, 10.1016/S0140-6736(14)60421-9

Thông tin
Thông tin xuất bản

Cancer Immunology Research

Tập 3 Số 6

620-630

Thông tin tác giả